JP2005341968A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005341968A5 JP2005341968A5 JP2005161155A JP2005161155A JP2005341968A5 JP 2005341968 A5 JP2005341968 A5 JP 2005341968A5 JP 2005161155 A JP2005161155 A JP 2005161155A JP 2005161155 A JP2005161155 A JP 2005161155A JP 2005341968 A5 JP2005341968 A5 JP 2005341968A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- nucleic acid
- seq
- cell
- neublastin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102100026376 Artemin Human genes 0.000 claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 101000785776 Homo sapiens Artemin Proteins 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims 18
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 13
- 238000000034 method Methods 0.000 claims 12
- 238000004519 manufacturing process Methods 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000001963 growth medium Substances 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 108700005078 Synthetic Genes Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000000472 traumatic effect Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 210000001178 neural stem cell Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 102000024452 GDNF Human genes 0.000 description 3
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 241001529936 Murinae Species 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199800904 | 1998-07-06 | ||
| US9222998P | 1998-07-09 | 1998-07-09 | |
| DKPA199801048 | 1998-08-19 | ||
| US9777498P | 1998-08-25 | 1998-08-25 | |
| DKPA199801265 | 1998-10-06 | ||
| US10390898P | 1998-10-13 | 1998-10-13 | |
| US09/347,613 US6593133B1 (en) | 1998-07-06 | 1999-07-02 | Neurotrophic factors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000558205A Division JP2002519061A (ja) | 1998-07-06 | 1999-07-05 | 神経栄養因子 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005326745A Division JP2006122053A (ja) | 1998-07-06 | 2005-11-10 | 神経栄養因子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005341968A JP2005341968A (ja) | 2005-12-15 |
| JP2005341968A5 true JP2005341968A5 (enExample) | 2006-02-02 |
Family
ID=27561795
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000558205A Pending JP2002519061A (ja) | 1998-07-06 | 1999-07-05 | 神経栄養因子 |
| JP2005161155A Withdrawn JP2005341968A (ja) | 1998-07-06 | 2005-06-01 | 神経栄養因子 |
| JP2005326745A Withdrawn JP2006122053A (ja) | 1998-07-06 | 2005-11-10 | 神経栄養因子 |
| JP2007120282A Withdrawn JP2007252381A (ja) | 1998-07-06 | 2007-04-27 | 神経栄養因子 |
| JP2007307603A Pending JP2008133282A (ja) | 1998-07-06 | 2007-11-28 | 神経栄養因子 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000558205A Pending JP2002519061A (ja) | 1998-07-06 | 1999-07-05 | 神経栄養因子 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005326745A Withdrawn JP2006122053A (ja) | 1998-07-06 | 2005-11-10 | 神経栄養因子 |
| JP2007120282A Withdrawn JP2007252381A (ja) | 1998-07-06 | 2007-04-27 | 神経栄養因子 |
| JP2007307603A Pending JP2008133282A (ja) | 1998-07-06 | 2007-11-28 | 神経栄養因子 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US6593133B1 (enExample) |
| EP (2) | EP1095140B1 (enExample) |
| JP (5) | JP2002519061A (enExample) |
| KR (1) | KR100743376B1 (enExample) |
| AT (1) | ATE522609T1 (enExample) |
| AU (1) | AU755114B2 (enExample) |
| CA (1) | CA2336218C (enExample) |
| CY (1) | CY1112101T1 (enExample) |
| DK (1) | DK1095140T3 (enExample) |
| EE (1) | EE05590B1 (enExample) |
| ES (1) | ES2373173T3 (enExample) |
| HU (1) | HU227870B1 (enExample) |
| IS (1) | IS2835B (enExample) |
| NZ (1) | NZ508994A (enExample) |
| PT (1) | PT1095140E (enExample) |
| SI (1) | SI1095140T1 (enExample) |
| TR (1) | TR200100056T2 (enExample) |
| WO (1) | WO2000001815A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
| US20020055467A1 (en) * | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
| HK1045528B (zh) * | 1998-07-14 | 2006-10-27 | 詹森药业有限公司 | 神经营养生长因子 |
| US7067473B1 (en) * | 1998-07-14 | 2006-06-27 | Janssen Pharmaceutica N.V. | Neurotrophic growth factor |
| US6284540B1 (en) * | 1998-09-29 | 2001-09-04 | Washington University | Artemin, a novel neurotrophic factor |
| EP1137774A2 (en) * | 1998-12-09 | 2001-10-04 | Amgen Inc. | Grnf4, a gdnf-related neurotrophic factor |
| CA2367375A1 (en) * | 1999-03-15 | 2000-09-21 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| EP1820860A3 (en) * | 1999-06-02 | 2008-03-19 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| PL366333A1 (en) * | 2000-12-22 | 2005-01-24 | Genentech, Inc. | New use of artemin, a member of the gdnf ligand family |
| BR0206852A (pt) * | 2001-02-01 | 2005-05-03 | Biogen Inc | Conjugados de polìmero de neublastina e métodos para uso dos mesmos |
| US7442370B2 (en) * | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
| US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
| NZ529126A (en) * | 2001-03-28 | 2010-07-30 | Biogen Idec Inc | Use of neublastin polypeptides for treating allodynia, hyperalgesic pain and phantom pain |
| US20040077543A1 (en) * | 2001-03-28 | 2004-04-22 | Sah Dinah W. Y. | Treatment using neublastin polypeptides |
| AU2003249013A1 (en) * | 2002-07-09 | 2004-01-23 | Bristol-Myers Squibb Company | Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42 |
| JP4571776B2 (ja) * | 2002-11-05 | 2010-10-27 | Ｊｘ日鉱日石エネルギー株式会社 | 潤滑油組成物 |
| SI1594436T1 (sl) | 2003-01-31 | 2011-01-31 | Biogen Idec Inc | Mutirani neoblastin |
| ES2328640T3 (es) | 2003-04-18 | 2009-11-16 | Biogen Idec Ma Inc. | Neublastina conjugada con un polimero glicosilada. |
| WO2004108760A2 (en) | 2003-06-10 | 2004-12-16 | Nsgene A/S | Improved secretion of neublastin |
| US7598059B2 (en) | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
| US20060239966A1 (en) * | 2003-10-20 | 2006-10-26 | Tornoee Jens | In vivo gene therapy of parkinson's disease |
| ATE472333T1 (de) * | 2004-08-19 | 2010-07-15 | Biogen Idec Inc | Rückfaltung von proteinen der transforming-growth-factor-beta-familie |
| UA92590C2 (uk) * | 2004-08-19 | 2010-11-25 | Байоджен Айдек Ма Інк. | Варіанти нейбластину |
| AU2006281798A1 (en) | 2005-08-16 | 2007-02-22 | Copenhagen University | GDNF derived peptides |
| WO2007042040A2 (en) * | 2005-10-11 | 2007-04-19 | Ns Gene A/S | TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS |
| TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
| WO2007103182A2 (en) * | 2006-03-01 | 2007-09-13 | Biogen Idec Ma Inc. | Compostions and methods for administering gdnf ligand family proteins |
| AU2008247637B2 (en) | 2007-05-01 | 2013-12-05 | Biogen Ma Inc. | Compositions and methods for increasing vascularization |
| AU2008269689A1 (en) * | 2007-06-27 | 2008-12-31 | Auckland Uniservices Limited | Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof |
| WO2009020964A2 (en) * | 2007-08-08 | 2009-02-12 | Biogen Idec Ma Inc. | Anti-neublastin antibodies and uses thereof |
| TWI775096B (zh) | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| WO2014152511A1 (en) | 2013-03-15 | 2014-09-25 | The Jackson Laboratory | Methods for promoting wound healing and hair growth |
| AU2014337504B2 (en) | 2013-10-14 | 2020-01-30 | Indiana University Research And Technology Corporation | Use of acamprosate to modulate ERK 1-2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD |
| KR102288849B1 (ko) | 2014-03-17 | 2021-08-12 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법 |
| EP3256147B8 (en) * | 2015-01-18 | 2020-10-21 | Gloriana Therapeutics, Inc. | Therapeutic protein formulations |
| KR20170137730A (ko) | 2015-03-02 | 2017-12-13 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법 |
| GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
| US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
| DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
| US5082670A (en) | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5084350A (en) | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
| US5618531A (en) | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
| DK0585368T3 (da) | 1991-04-25 | 1998-03-16 | Univ Brown Res Found | Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter |
| DK0606217T4 (da) | 1991-06-27 | 2009-03-30 | Bristol Myers Squibb Co | CTL4-receptor, fusionsproteiner indeholdende den samt anvendelse deraf |
| CA2112674C (en) | 1991-07-02 | 2005-10-04 | John S. Patton | Method and device for delivering aerosolized medicaments |
| US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| MX9205293A (es) | 1991-09-20 | 1993-05-01 | Syntex Sinergen Neuroscience J | Factores neurotrofico derivado del glial |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5284350A (en) * | 1992-05-22 | 1994-02-08 | Medical Composite Technology | Foldable wheelchair and side frame assembly |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| KR100291620B1 (ko) | 1992-09-29 | 2001-10-24 | 추후제출 | 부갑상선호르몬의활성단편의폐를통한전달방법 |
| CA2092271C (en) | 1993-03-09 | 2009-10-13 | Eddie Reed | Use of g-csf for treating taxol side-effects |
| CA2169292C (en) | 1993-08-12 | 2010-11-23 | E. Edward Baetge | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
| DE4339605A1 (de) | 1993-11-20 | 1995-05-24 | Beiersdorf Ag | Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden |
| US5834029A (en) | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
| US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US5739307A (en) | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
| US5733729A (en) | 1995-09-14 | 1998-03-31 | Affymetrix, Inc. | Computer-aided probability base calling for arrays of nucleic acid probes on chips |
| US5641749A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product |
| US6299895B1 (en) * | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| US6878544B2 (en) * | 1996-04-19 | 2005-04-12 | Neurotech Sa | Retinal cell lines with extended life-span and their applications |
| DE69736428T2 (de) | 1996-05-08 | 2007-08-30 | Biogen Idec Ma Inc., Cambridge | RET-LIGAND 3 (RetL3), UM NEURALES UND RENALES WACHSTUM ZU STIMULIEREN |
| US5754524A (en) | 1996-08-30 | 1998-05-19 | Wark; Barry J. | Computerized method and system for analysis of an electrophoresis gel test |
| KR100195886B1 (ko) | 1996-11-01 | 1999-06-15 | 김상조 | 당뇨병 치료용 의약조성물 |
| WO1998032869A1 (en) | 1997-01-29 | 1998-07-30 | Neurosearch A/S | Expression vectors and methods for in vivo expression of therapeutic polypeptides |
| US20020192209A1 (en) * | 1997-09-17 | 2002-12-19 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
| US20020055467A1 (en) * | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
| HK1045528B (zh) | 1998-07-14 | 2006-10-27 | 詹森药业有限公司 | 神经营养生长因子 |
| AU778998B2 (en) * | 1998-09-22 | 2004-12-23 | University Of Maryland At Baltimore | Cystine knot growth factor mutants |
| US6284540B1 (en) | 1998-09-29 | 2001-09-04 | Washington University | Artemin, a novel neurotrophic factor |
| EP1137774A2 (en) * | 1998-12-09 | 2001-10-04 | Amgen Inc. | Grnf4, a gdnf-related neurotrophic factor |
| DK1607402T3 (da) * | 1999-03-08 | 2007-04-16 | Genentech Inc | Sammensætninger og fremgangsmåder til tumorbehandling |
| US6361771B1 (en) * | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
| CA2373915A1 (en) * | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| JP2001329126A (ja) | 2000-05-22 | 2001-11-27 | Bridgestone Corp | 硬化性組成物 |
| EP1325966B1 (en) * | 2000-09-12 | 2009-04-01 | JFE Steel Corporation | Super-high strength cold-rolled steel sheet and method for production thereof |
| US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
| US20040077543A1 (en) * | 2001-03-28 | 2004-04-22 | Sah Dinah W. Y. | Treatment using neublastin polypeptides |
| US7598059B2 (en) * | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
-
1999
- 1999-07-02 US US09/347,613 patent/US6593133B1/en not_active Expired - Lifetime
- 1999-07-05 KR KR1020017000184A patent/KR100743376B1/ko not_active Expired - Fee Related
- 1999-07-05 EP EP99931023A patent/EP1095140B1/en not_active Expired - Lifetime
- 1999-07-05 HU HU0103758A patent/HU227870B1/hu not_active IP Right Cessation
- 1999-07-05 ES ES99931023T patent/ES2373173T3/es not_active Expired - Lifetime
- 1999-07-05 EE EEP200100008A patent/EE05590B1/xx not_active IP Right Cessation
- 1999-07-05 JP JP2000558205A patent/JP2002519061A/ja active Pending
- 1999-07-05 NZ NZ508994A patent/NZ508994A/en not_active IP Right Cessation
- 1999-07-05 TR TR2001/00056T patent/TR200100056T2/xx unknown
- 1999-07-05 PT PT99931023T patent/PT1095140E/pt unknown
- 1999-07-05 DK DK99931023.8T patent/DK1095140T3/da active
- 1999-07-05 CA CA2336218A patent/CA2336218C/en not_active Expired - Fee Related
- 1999-07-05 SI SI9931062T patent/SI1095140T1/sl unknown
- 1999-07-05 EP EP10181304A patent/EP2290079A3/en not_active Withdrawn
- 1999-07-05 AT AT99931023T patent/ATE522609T1/de active
- 1999-07-05 AU AU47693/99A patent/AU755114B2/en not_active Ceased
- 1999-07-05 WO PCT/DK1999/000384 patent/WO2000001815A2/en not_active Ceased
-
2000
- 2000-09-15 US US09/662,183 patent/US6734284B1/en not_active Expired - Lifetime
- 2000-12-14 IS IS5769A patent/IS2835B/is unknown
-
2004
- 2004-03-22 US US10/806,793 patent/US20040230043A1/en not_active Abandoned
-
2005
- 2005-06-01 JP JP2005161155A patent/JP2005341968A/ja not_active Withdrawn
- 2005-11-10 JP JP2005326745A patent/JP2006122053A/ja not_active Withdrawn
-
2007
- 2007-04-27 JP JP2007120282A patent/JP2007252381A/ja not_active Withdrawn
- 2007-10-31 US US11/932,744 patent/US20080227703A1/en not_active Abandoned
- 2007-11-28 JP JP2007307603A patent/JP2008133282A/ja active Pending
-
2009
- 2009-10-27 US US12/606,602 patent/US20100234293A1/en not_active Abandoned
-
2011
- 2011-04-11 US US13/084,267 patent/US20120252726A1/en not_active Abandoned
- 2011-11-29 CY CY20111101173T patent/CY1112101T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005341968A5 (enExample) | ||
| CA2336218A1 (en) | Neurotrophic factors | |
| JP6449356B2 (ja) | ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド | |
| US20210032616A1 (en) | Factor ix fusion proteins and methods of making and using same | |
| CN1159439C (zh) | 泛向神经营养因子 | |
| JPH07502404A (ja) | 幹細胞阻害タンパク質 | |
| JP6230158B2 (ja) | ヒトβ−ヘキソサミニダーゼＢの基質特異性を変換し、且つ、プロテアーゼ抵抗性を付与した新規高機能酵素 | |
| US20190153406A1 (en) | MG53 Mutants, Methods of Making the Same, and Uses Thereof | |
| Olsen et al. | Expression and characterization of a low molecular weight recombinant human gelatin: development of a substitute for animal-derived gelatin with superior features | |
| TW202222337A (zh) | 一種提高bdnf水平的方法和藥物 | |
| US8383130B2 (en) | Partial peptide of lacritin | |
| Luo et al. | Identification of maze learning-associated genes in rat hippocampus by cDNA microarray | |
| TW202146648A (zh) | 人類α-半乳糖苷酶變異體 | |
| JP2003512841A5 (enExample) | ||
| JP2005511015A5 (enExample) | ||
| EP4365190A1 (en) | Recombinant botulinum toxin type a light chain, recombinant botulinum toxin, and composition, use, and method thereof | |
| JP5678664B2 (ja) | ヒトβ−ヘキソサミニダーゼＢの基質特異性を変換した新規高機能酵素 | |
| EP4365191A1 (en) | Recombinant botulinum toxin type a light chain, recombinant botulinum toxin, and composition, use, and method thereof | |
| US20080102463A1 (en) | Gene 4 | |
| US20240132865A1 (en) | Pharmaceutical composition for treating, preventing or ameliorating gm1 gangliosidosis or morquio syndrome b and administration method thereof | |
| KR102728382B1 (ko) | 보툴리눔 독소의 경쇄 변이체 | |
| JP2003164290A5 (enExample) | ||
| CN120035662A (zh) | 用于治疗、预防或改善GM1神经节苷脂沉积症或Morquio综合征B的药物组合物及其施用方法 | |
| WO2024238698A2 (en) | Transcription factor 4 gene editing system | |
| KR101860103B1 (ko) | 인터페론-베타 신호 펩타이드 변이체 및 이의 용도 |